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The estimate of new cancer cases reached 18.1 
million worldwide in 2018 [1], with a constantly growing 
trend that needs to be contrasted by efficacious (chemo)
preventive strategies able to counteract the dreadful 
global burden of this disease [2]. Several preclinical, 
epidemiological and clinical studies proposed non-
steroidal anti-inflammatory drugs (NSAIDs) as one of the 
most promising class of compounds for the prevention of 
different cancer types, including mammary tumors [3], 
even if their use in long-term treatment is limited by side 
effects due to cyclooxygenase (COX) inhibition.
Recently, we identified SIRT1 as a novel target 
for NSAID chemopreventive activity, independent 
from COX [4]. SIRT1 is the mammalian homolog of 
yeast silent information regulator 2 (Sir2), member of 
the NAD+-dependent class III histone deacetylases. 
SIRT1 deacetylates various protein substrates including 
histones, DNA-repair, intracellular signaling and 
transcription factors; because of this pleiotropic action, 
SIRT1 has been implicated in the regulation of several 
biological processes related with cancer such as energetic 
metabolism, proliferation, inflammation, apoptosis and 
hypoxia [5]. Our work demonstrated that NSAIDs with 
different chemical structures can directly interact with the 
enzyme and inhibit its deacetylase activity. Because of the 
SIRT1 inhibition, the oncosuppressor p53/P21 pathway 
is activated and counteracts the cell hyperproliferation 
occurring during initial tumorigenesis steps in preclinical 
breast cancer models and in patients [4]. Although 
several studies reported a controversial role for SIRT1 
inhibition in tumorigenesis, a recent phase III clinical trial 
investigating the effects of nicotinamide (vitamin B3, the 
physiological inhibitor of SIRT1) in non-melanoma skin 
cancer demonstrated the ability of this vitamin to reduce 
the rates of new tumorigenic events in high-risk patients 
characterized by immunosuppression and DNA repair 
defect. In these patients, nicotinamide administration 
increased the level of pro-inflammatory cytokines and 
stimulated DNA repair, thus significantly reducing the risk 
of tumor onset [6]. This clinical result, substantiated by 
several preclinical studies [7], points to SIRT1 inhibition as 
a potential strategy for cancer prevention using a candidate 
drug of natural origin, nicotinamide, particularly attractive 
for a non-toxic, cheap chemopreventive treatment. 
                  Editorial
Figure 1: Nicotinamide and NSAIDs are binding and inhibiting SIRT1 deacetylase. The enzymatic inhibition by these molecules 
stimulates the anti-proliferative p53/P21 pathway reducing the risk of invasive breast cancer insurgence.
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Our finding demonstrating the ability of  NSAIDs 
to inhibit SIRT1 and activate p53/P21 signaling is 
particularly intriguing in light of recent epidemiological 
data associating the perioperative administration of 
ketorolac and diclofenac with a significant reduction 
of relapse events in breast and ovary cancer patients 
[8, 9], especially for those with increased BMI [10]. The 
repurposing of these NSAIDs in cancer prevention is 
currently under consideration in clinical trials designed 
to support the epidemiological findings.  In our work, 
we observed that in breast cancer patients receiving 
ketorolac as antalgic treatment during mastectomy, the 
SIRT1-p53 pathway is selectively activated by the NSAID 
administration [4], suggesting a direct association between 
SIRT1 inhibition and the reduction of recurrence risk in 
these patients. 
The clinical relevance of the p53/P21 pathway 
stimulation produced by SIRT1 inhibitors in the 
active prevention of mammary cancer has never been 
investigated. Our study provides the rational basis for 
a prospective clinical trial aiming at the evaluation of 
nicotinamide effects on p53/P21 pathway and relapse 
risk in breast cancer patients undergoing mastectomy 
(Figure 1). Using nicotinamide as SIRT1 inhibitor, it 
would be possible to evaluate the effects of the long-term 
enzymatic inhibition after mastectomy that is expected 
to reduce the relapse risk to a major extent compared to 
the perioperatory ketorolac or diclofenac administration. 
In this sense, nicotinamide represents a better candidate 
drug respect to NSAIDs, whose sub-optimal safety 
profile limits their use only to short-term treatments (e.g. 
during the antalgic therapy in the surgery procedure). In 
conclusion, our study casts the evidence for the chronic 
use of vitamin B3 after mastectomy to actively prevent the 
progression into a life-threatening disease; moreover, this 
can be an initial proof-of-principle for a wider application 
of nicotinamide treatment in cancer chemoprevention 
beyond breast and skin cancer fields.
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